In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, ...

Eli Lilly is a well-established pharmaceutical company with a portfolio of products that consistently generate revenue and ...

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an initial public offering (IPO) in Hong ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts.

Wall Street ends 2026 positively with tech stocks dominating, but concerns over valuations drive interest in smaller AI ...

Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer—has long captured the public imagination. Yet most arguments about it rest ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Ethereum Foundation set 2026 zkEVM security targets using soundcalc. ETH also nears a multi month trendline test near $3,030.